OncoMatch/Clinical Trials/NCT06608732
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Is NCT06608732 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Inaticabtagene autoleucel for b-cell acute lymphoblastic leukemia.
Treatment: Inaticabtagene autoleucel — Evaluate the safety and efficacy of Inaticabtagene autoleucel combined with autologous hematopoietic stem cell transplantation in adolescents or adults with MRD-positive initial complete remission in B-cell acute lymphoblastic leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR BCR-ABL1 > 0% detected by routine q-PCR technology (BCR-ABL1 > 0%)
patients with BCR-ABL1 > 0% detected by routine q-PCR technology
Disease stage
Required: Stage CR1
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: induction chemotherapy — standard (Ph-negative) or guideline-recommended (Ph-positive); TKI allowed for Ph-positive
achieving CR1 after standard induction chemotherapy (Ph-negative) or guideline-recommended induction chemotherapy (or use of TKI) (Ph-positive)
Must have received: consolidation therapy — at least one
undergoing at least one consolidation therapy
Cannot have received: CAR-T cell therapy
Individuals who have received CAR-T cell therapy before screening or pre-treatment
Cannot have received: hematopoietic stem cell transplantation
patients who have undergone hematopoietic stem cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06608732 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, hematopoietic stem cell transplantation disqualifies patients from enrollment.
Does this trial require BCR?
Yes, BCR BCR-ABL1 > 0% detected by routine q-PCR technology is a required biomarker for enrollment.
What disease stage is eligible?
Stage CR1 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 16 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify